GlassScriptPhysician profile
Douglas Paine
NPI 1386646073
$3,716.48
in general payments reported to CMS, 2019-2025
30 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,766 · 2020: $1,039 · 2021: $912.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $669.13 | 2019-2021 | |
| Ucb, INC. | $509.17 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $308.98 | 2019-2021 | |
| Lundbeck LLC | $300.70 | 2019-2021 | |
| Avanir Pharmaceuticals, INC. | $244.39 | 2019-2021 | |
| Alexion Pharmaceuticals, INC. | $198.18 | 2019-2021 | |
| Emd Serono, INC. | $194.99 | 2019-2021 | |
| Sk Life Science, INC. | $182.68 | 2020-2021 | |
| Amgen INC. | $150.71 | 2019-2021 | |
| Lilly USA, LLC | $122.44 | 2019-2021 | |
| Adamas Pharmaceuticals, INC. | $98.07 | 2019-2021 | |
| Eisai INC. | $93.35 | 2019-2021 | |
| Amneal Pharmaceuticals LLC | $78.35 | 2019-2021 | |
| Kyowa Kirin, INC. | $70.30 | 2019-2021 | |
| Acadia Pharmaceuticals INC | $65.74 | 2019-2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurelis, INC. | $64.78 | 2020-2021 | |
| Mdd US Operations, LLC | $54.38 | 2019 | |
| Livanova USA, INC. | $50.80 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $37.96 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $33.92 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $30.29 | 2020 | |
| Tanabe Pharma America, INC. | $26.77 | 2019 | |
| Banner Life Sciences, LLC | $25.88 | 2021 | |
| Mallinckrodt Hospital Products INC. | $18.81 | 2020 | |
| Janssen Pharmaceuticals, INC | $16.26 | 2021 | |
| Upsher-Smith Laboratories LLC | $15.57 | 2021 | |
| Abbvie INC. | $15.21 | 2021 | |
| Acorda Therapeutics, INC | $14.54 | 2019 | |
| Genentech USA, INC. | $12.32 | 2019 | |
| Allergan, INC. | $11.81 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Paine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.